Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials

• Published in: American journal of cardiovascular drugs : drugs, devices, and other interventions Vol. 17; no. 2; pp. 143 - 155
• Main Authors: Elgendy, Islam Y., Mahmoud, Ahmed N., Barakat, Amr F., Elgendy, Akram Y., Saad, Marwan, Abuzaid, Ahmed, Wayangankar, Siddarth A., Bavry, Anthony A.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.04.2017; Springer Nature B.V
• Subjects: Cardiology; Cardiovascular Diseases - chemically induced; Cardiovascular Diseases - epidemiology; Diabetes; Diabetes Mellitus, Type 2 - drug therapy; Dipeptidyl-Peptidase IV Inhibitors - adverse effects; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; Health risk assessment; Heart attacks; Heart failure; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Medicine; Medicine & Public Health; Meta-analysis; Mortality; Original Research Article; Pharmacology/Toxicology; Pharmacotherapy; Randomized Controlled Trials as Topic; Stroke; Studies; Heart Failure; Sitagliptin; Cardiovascular Outcome; Vildagliptin; Ischemic Stroke

Background Large randomized trials have shown conflicting evidence regarding the cardiovascular safety of dipeptidyl-peptidase 4 (DPP-4) inhibitors. Systematic reviews have been limited by incomplete data and inclusion of observational studies. This study aimed to systematically evaluate the cardiov...